linjc16/ctgov huggingface dataset:
Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate efficacy of two different intravenous drugs (dimenhydrinate and piracetam) in the symptomatic management of peripheral vertigo. The patients will be randomized in two groups according to symptomatic treatment modalities: Dimenhydrinate (100 mg) and piracetam (2 g) will be given in 100 cc normal saline in 30 minutes. Each patient will be asked if her/his vertigo symptoms resolved or not, according to a numeric rating scale (0=no vertigo, 10=worst possible vertigo). The patient will be rate the intensity of symptoms in the following times: Numeric rating scale (1 to 10): Admission Numeric rating scale (1 to 10): After the study drug (No ambulation)* Numeric rating scale (1 to 10): After the study drug (Ambulation)* Ambulation refers to head movements or walking in the room, if applicable.

Official Title
-----------------
Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo: A Double Blind Randomized Clinical Trial

Conditions
-----------------
Peripheral Vertigo

Intervention / Treatment
-----------------
* Drug: Administration of 100 mg dimenhydrinate intravenous
* Drug: 2 g piracetam intravenous


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presenting to emergency department with vertigo symptoms Adult patients (over 18) Agree to participate to study (understanding the study protocol and signing the informed consent form) Exclusion Criteria: Patients under 18 years Patients diagnosed with ischemic/hemorrhagic stroke after neuroimaging Patient diagnosed with transient ischemic attack Pregnants Patients taking any analgesics or antihistaminic drugs last 24 hours Documented or declared allergy to dimenhydrinate, piracetam or benzodiazepines Patients who do not agree to participate to the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Piracetam<br>2 g intravenous piracetam | Drug: 2 g piracetam intravenous<br> <br> |
| Active Comparator: Dimenhydrinate<br>Dimenhydrinate 100 mg intravenous | Drug: Administration of 100 mg dimenhydrinate intravenous<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in numeric rating scale |  | Change from baseline in numeric rating scale at 30th minute | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vertigo, dimenhydrinate, piracetam
Green Coffee Extract and Metabolic Syndrome

Study Overview
=================
Brief Summary
-----------------
Metabolic syndrome (Mets) is an assemblage of risk factors which can increase the risk of developing type 2 diabetes mellitus and cardiovascular disease. Green coffee extract (GCE) is derived from unroasted coffee beans and has substantial amounts of polyphenols primarily chlorogenic acids (CGA). It has been shown that GCE and CGA can exert a positive influence over Mets components including blood pressure, blood glucose, inflammation, oxidative stress, insulin resistance and blood lipids. Up to our knowledge no study has been conducted on humans in the field of GCA influences on Mets patients. Therefore, this study is planned to evaluate GCA supplementation effects on anthropometric measurements, glycemic control, blood pressure, lipid profile in patients with metabolic syndrome.

Official Title
-----------------
Effects of Green Coffee Extract Supplementation on Anthropometric Measurements, Glycemic Control, Blood Pressure, Lipid Profile

Conditions
-----------------
Metabolic Syndrome

Intervention / Treatment
-----------------
* Dietary Supplement: green coffee extract
* Dietary Supplement: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Waist circumference>102 cm in men and >88 cm in women Fasting blood glucose>100 mg/dL (5.6 mmol /L) Systolic blood pressure>130 mmHg or diastolic blood pressure>85mmHg Triglycerides> 150 mg/dL (1.7 mmol/L) Exclusion Criteria: Insulin administration Pregnancy and breastfeeding regular consumption of coffee and green tea

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: intervention<br>400 mg green coffee extract capsules twice per day for 8 weeks The Green coffee extract is standardised with 45% total chlorogenic acid by HPLC | Dietary Supplement: green coffee extract<br> <br> |
| Placebo Comparator: control<br>placebo capsules twice per day for 8 weeks have identical appearance to Green coffee extract capsules and contain starch | Dietary Supplement: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fasting blood glucose |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HOMA-IR |  | 8 weeks | 
| blood pressure |  | 8 weeks | 
| insulin |  | 8 weeks | 
| hemoglubin A1c |  | 8 weeks | 
| triglyceride |  | 8 weeks |
Assessing Outcome After H-graft Shunt Placement

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the pre-operative symptoms and medical history of patients with portal hypertension who have undergone placement of H-graft portacaval shunts and correlate this with patient outcomes.

Detailed Description
-----------------
Research data will be collected by accessing the Tampa General Hospital medical record charts as well as the Harbourside medical charts, and extracting the necessary research data. The charts will be reviewed for the relevant medical information in order to assess outcomes in patients having H-graft shunts placed for the treatment of portal hypertension.

Official Title
-----------------
A Study Assessing Patient Outcomes After Placement of H-graft Portacaval Shunts for the Treatment of Portal Hypertension

Conditions
-----------------
Portal Hypertension

Intervention / Treatment
-----------------
* Other: Chart Review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have had H-graft shunts placed for the treatment of portal hypertension. Exclusion Criteria: Patients under the age of 18 will not be included in this study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| I<br>Patients will have charts reviewed for relevant medical information before and after surgery to assess patient outcome after placement of H-graft shunt for the treatment of portal hypertension. | Other: Chart Review<br>* Patients' charts will be reviewed for relevant medical information.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The objective of this study is to evaluate the pre-operative symptoms and medical history of patients with portal hypertension who have undergone placement of H-graft portacaval shunts and correlate this with patient outcomes. |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
portal hypertension, H-graft shunt
Image and Dosimetry Related Research of Department of Medical Physics, Cross Cancer Institute

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to retrospectively have access to image files of patients.

Official Title
-----------------
Image and Dosimetry Related Research of Department of Medical Physics, Cross Cancer Institute

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject 18 years of age and over

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Long Term Vascular Changes in Type 1 Diabetes

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to investigate progression of late complications of diabetes during the last ten years in a well characterized cohort of type 1 diabetes with a long duration of the disease, and to define factors responsible for the progression of late complications.

Detailed Description
-----------------
Despite intensively research in the field of hyperglycaemia and coronary heart disease in type 1 diabetes it is still not known in detail how hyperglycaemia leads to damage of the vessels. The aims of the present proposal are therefore two-fold: To study in detail the progression of atherosclerosis (and micro vascular complications) in a well characterized cohort of type 1 diabetes with a long duration of the disease. This project will be a continuation of the Oslo study, a cohort started in 1982, with the last follow-up study in 1999/2000. To define factors responsible for the progression of coronary heart disease (and micro vascular complications) in this cohort.

Official Title
-----------------
Long Term Vascular Changes in Type 1 Diabetes, Clinical Aspects and Biological Markers

Conditions
-----------------
Diabetes Mellitus, Type 1, Complications, Coronary Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
The original criteria from 1982: Inclusion Criteria: Age 18-45 years Diagnosis of type 1 diabetes at < 30 years of age, disease duration > 7 but < 30 years C-peptide < 0, 1 nmol/l Exclusion Criteria: Serum creatinine > 150 µmol/l Diastolic blood pressure <100mmHg Overt nephropathy Proliferative retinopathy Pregnancy A history of neuropathy Other chronical disease Treatment with other drugs except insulin and oral contraceptives

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetes, type 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fatal and non fatal cardiovascular disease (CVD) and stroke |  | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vessel area stenosis |  | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes mellitus, type1, cardiovascular disease, diabetes complications, Glycation end products, advanced
Impact of n-3 Polyunsaturated Fatty Acids in a Protein-enriched Diet With Low GI in Type 2 Diabetes Patients

Study Overview
=================
Brief Summary
-----------------
Type 2 diabetes is tightly associated with overweight and obesity. Inflammatory processes are crucial triggers for insulin resistance that paves the way to type 2 diabetes. In a previous study the investigators have shown that n-3 polyunsaturated fatty acids diminish adipose tissue inflammation in morbidly obese non-diabetic subjects. in this observational study the investigators will apply n-3 polyunsaturated fatty acids as addition to a protein-enriched diet with low glycemic index to overweight and obese patients with insulin resistance, prediabetes and manifest type 2 diabetes over up to 6 months. Primary efficacy parameters are changes from baseline in HbA1c and body weight for for type 2 diabetes and all other patients, respectively.

Official Title
-----------------
IMpact of n-3 Polyunsaturated Fatty Acids With a Protein-Enriched DiEt With Low Glycemic Index on Metabolic and Inflammatory Parameters in Type 2 Diabetic and Obese Patients: an Observational Pilot Study

Conditions
-----------------
Overweight, Obese, Insulin Resistance, Diabetes

Intervention / Treatment
-----------------
* Dietary Supplement: n-3 PUFA in protein-enriched low-GI diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: overweight or obesity AND insulin resistant OR pre-diabetes OR type 2 diabetes Exclusion Criteria: changes in anti-diabetic medication in the lat two months acute illness during the last two weeks HIV infection hepatitis of other clinically significant hepatic disease other than non-alcoholic hepatic steatosis severe or insufficiently treated cardiovascular, renal (GFR-MDRD < 60 ml/min) or pulmonary disease Macroproteinuria (> 300 mg/g creatinine) clinically significant or insufficiently treated thyroid disease anemia active malignant disease inborn or acquired coagulopathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>overweight or obese diabetic | Dietary Supplement: n-3 PUFA in protein-enriched low-GI diet<br>* 3 g per day n-3 polyunsaturated fatty acids in a protein-enriched low-GI diet<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c change from baseline (type 2 diabetes patients) |  | 3 months | 
| body weight change from baseline (non-diabetic patients) |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change from baseline of inflammatory and metabolic parameters |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
observational study
Different Regulation of Immune Cells in Patients With Preeclampsia

Study Overview
=================
Brief Summary
-----------------
Adaptation of the maternal immune system to accommodate the semi-allogeneic fetus is necessary for pregnancy success. Dysregulation of this immune adaptation is implicated in reproductive disorders as infertility, recurrent miscarriage, fetal growth restriction, and preeclampsia. The mechanisms being responsible for fetal tolerance are not known. Several T cell subsets have been implicated in fetal tolerance. The effects of preeclampsia on memory cells are not known. The main objective of this study is to analyze the effect of preeclampsia on levels of immune cells.

Conditions
-----------------
Preeclampsia, Pregnancy

Intervention / Treatment
-----------------
* Procedure: Blood withdrawal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy written informed consent 18-40 years Exclusion Criteria: smoking immune related disorders (other than preeclampsia) fever / illness within the last month infertility body mass index <18 or >30

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy<br>Healthy women | Procedure: Blood withdrawal<br> <br> |
| Preeclamptic<br>Pregnant women with preeclampsia | Procedure: Blood withdrawal<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cell levels |  | 1 year |
Oasys vs. Extreme H20 Xtra 59

Study Overview
=================
Brief Summary
-----------------
To compare the performance of Oasys to Extreme H20 xtra 59 in dry eye contact lens pts who receive Restasis in 1 eye and vehicle (Endura) in the other eye.

Official Title
-----------------
Oasys vs. Extreme H20 Xtra 59

Conditions
-----------------
Dry Eye

Intervention / Treatment
-----------------
* Drug: Restasis, Refresh Endura


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female at least 19 years of age Contact Lens Wearers Patients with mild to moderate symptoms of dry eye Exclusion Criteria: male or female younger than 19 years of age

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Drug: Restasis, Refresh Endura<br>* Restasis 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening Refresh Endura 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening<br>|
| Placebo Comparator: 2<br> | Drug: Restasis, Refresh Endura<br>* Restasis 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening Refresh Endura 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comparing performance of contact lens |  | 10 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dry eye |  | 10 months |
Smart Cupboard-based System for Memory Assessment in Alzheimer's Patients

Study Overview
=================
Brief Summary
-----------------
The main objective of the research is to create a tool that can make a good diagnosis of cognitive abilities in Alzheimer's patients. As a secondary objective, the investigators intend to examine both the percentage of correct answers and the response times and see their relationship with age, gender, sex, months since the onset of the disease and years of training.

Official Title
-----------------
Smart Cupboard-based System for Memory Assessment in Alzheimer's Patients

Conditions
-----------------
Alzheimer Disease, Cognitive Decline

Intervention / Treatment
-----------------
* Other: Smart cupboard


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being over 18 years. Provide signed informed consent. Have the ability to understand the study. Exclusion Criteria: Having any physical or medical problem that prevents or advises them not to stand upright, in a bipedal position.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental<br>Alzheimer´s patients | Other: Smart cupboard<br>* Development of a memory task with the help of a smart cupboard<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy response. | Number of successes / failures on the total of questions | 60 minutes | 
| Reaction time | Defined as the time it takes the subject to answer each of the questions. | 60 minutes |
Anxiety and Sexual Malfunction Functions in Infertile Pcos Women

Study Overview
=================
Brief Summary
-----------------
Polycystic ovary syndrome (PCOS) is acommon hormonal disorder in females in reproductive age associated with signs and symptoms as amenorrhea or oligomenorrhea, obesity,infertility acne and hairsutism that mostly Reduce self steem and havig negative impact on physical and sexual quality of life , the management of signs and symptoms should result in improvement in the quality of life

Detailed Description
-----------------
PCOS is also one of the leading causes of infertility, and infertility has been reported as an important source of stress. Infertility and subfertility in women with PCOS cause a decrease in women's quality of life and a positive perception of their bodies. Several studies have reported that female infertility has adverse effects on sexual satisfaction, and it is believed that fertility and anxiety in PCOS affects sexual functions, independent of other components of the disease. In addition, women with PCOS are more concerned about fertility than their healthy peers, and this concern may affect their overall quality of life.In light of these studies, infertility may have a negative effect on anxiety and also sexual function.Sexual functions and satisfaction have important implications on the overall state of well-being, and a decrease in the quality of sexual life negatively affects participation in social life, Besides it, PCOS causes problems in terms of sexual dysfunction .further studies are needed to clarify the effects of PCOS on sexual function in Infertile women .

Official Title
-----------------
Anxiety and Sexual Malfunction in Infertile Polycystic Ovarian Syndrome Patients

Conditions
-----------------
Quality of Life

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Age:20-40 Married infertile Exclusion Criteria: any other diseases could affect quality of life

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevellance of anxiety and sexual malfunction | Anticipated | 6 months |